{"id":"mibefradil","rwe":[{"pmid":"41819735","year":"2026","title":"Drug-drug interaction by metabolites: Challenges and solutions during therapeutics innovation.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"},{"pmid":"41403024","year":"2026","title":"Recurrent CACNA1HE282K is a gain-of-function mutation associated with primary hyperaldosteronism.","finding":"","journal":"European journal of endocrinology","studyType":"Clinical Study"},{"pmid":"40907630","year":"2025","title":"The role and behavior of voltage-gated calcium channels in ischemia/reperfusion.","finding":"","journal":"Cellular signalling","studyType":"Clinical Study"},{"pmid":"40859969","year":"2025","title":"Identification and Validation of Antidepressant Small Molecules Using Bioinformatics and Mouse Depression Models.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"},{"pmid":"40624735","year":"2025","title":"A New Method for Antispastic Effect in Coronary Artery Bypass Grafts by Using a L- and T-Type Calcium Channel Blocker Efonidipine.","finding":"","journal":"Basic & clinical pharmacology & toxicology","studyType":"Clinical Study"}],"tags":[{"label":"mibefradil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent T-type calcium channel subunit alpha-1I","category":"target"},{"label":"CACNA1I","category":"gene"},{"label":"KCNH2","category":"gene"},{"label":"CACNA1G","category":"gene"},{"label":"C08CX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Angina pectoris","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Approved 1990s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Cytochrome P-450 CYP1A2 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 Enzyme Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Metabolic Side Effects of Drugs and Substances","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/alfuzosin","drug":"alfuzosin","action":"Avoid combination","effect":"May interact with Alfuzosin, Mibefradil Dihydrochloride","source":"DrugCentral","drugSlug":"alfuzosin"},{"url":"/drug/silodosin","drug":"silodosin","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride, Silodosin","source":"DrugCentral","drugSlug":"silodosin"},{"url":"/drug/tamsulosin","drug":"tamsulosin","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride, Tamsulosin Hydrochloride","source":"DrugCentral","drugSlug":"tamsulosin"},{"url":"/drug/terfenadine","drug":"terfenadine","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride, Terfenadine","source":"DrugCentral","drugSlug":"terfenadine"}],"contraindications":["Atrioventricular Conduction Defect","Complete atrioventricular block","Disease of liver","Sick sinus syndrome"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MIBEFRADIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:58:23.606900+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:58:30.472089+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIBEFRADIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:58:31.248088+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Voltage-gated T-type calcium channel blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:58:31.837970+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1534525/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:58:31.727596+00:00"}},"allNames":"posicor","offLabel":[],"synonyms":["mibefradil","mibefradil dihydrochloride","posicor","Ro 40-5967"],"timeline":[{"date":"1997-08-01","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1997-08-01","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Posicor","ecosystem":[{"indication":"Angina pectoris","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"bepridil","slug":"bepridil","company":""}],"globalPrevalence":112000000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Voltage-dependent T-type calcium channel subunit alpha-1I","novelty":"Follow-on","targets":[{"gene":"CACNA1I","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1I","protein":"Voltage-dependent T-type calcium channel subunit alpha-1I"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"CACNA1G","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1G","protein":"Voltage-dependent T-type calcium channel subunit alpha-1G"},{"gene":"CACNA1H","source":"DrugCentral","target":"Voltage-dependent T-type calcium channel subunit alpha-1H","protein":"Voltage-dependent T-type calcium channel subunit alpha-1H"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"},{"gene":"SCN9A","source":"DrugCentral","target":"Sodium channel protein type 9 subunit alpha","protein":"Sodium channel protein type 9 subunit alpha"},{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"CACNA1B","source":"DrugCentral","target":"Voltage-dependent N-type calcium channel subunit alpha-1B","protein":"Voltage-dependent N-type calcium channel subunit alpha-1B"},{"gene":"ABCB1","source":"DrugCentral","target":"Multidrug resistance protein 1","protein":"Multidrug resistance protein 1"},{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1C","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"}],"modality":"Small Molecule","drugClass":"mibefradil","explanation":"","oneSentence":"","technicalDetail":"Posicor (mibefradil) selectively and competitively blocks the voltage-dependent T-type calcium channel subunit alpha-1I, inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells, which leads to vasodilation and reduced cardiac contractility."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-08-01, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1797","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIBEFRADIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIBEFRADIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:43:45.238044","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:58:33.618991+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"benzocaine","drugSlug":"benzocaine","fdaApproval":"","relationship":"same-target"},{"drugName":"benzonatate","drugSlug":"benzonatate","fdaApproval":"1958-02-10","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bepridil","drugSlug":"bepridil","fdaApproval":"1990-12-28","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"bupivacaine","drugSlug":"bupivacaine","fdaApproval":"1972-10-03","patentExpiry":"Mar 17, 2042","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"carbamazepine","drugSlug":"carbamazepine","fdaApproval":"1968-03-11","patentExpiry":"Nov 10, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cinchocaine","drugSlug":"cinchocaine","fdaApproval":"","relationship":"same-target"},{"drugName":"dextropropoxyphene","drugSlug":"dextropropoxyphene","fdaApproval":"1957-08-16","relationship":"same-target"},{"drugName":"disopyramide","drugSlug":"disopyramide","fdaApproval":"1977-09-01","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"mibefradil","indications":{"approved":[{"name":"Angina pectoris","source":"DrugCentral","snomedId":194828000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"benzocaine","brandName":"benzocaine","genericName":"benzocaine","approvalYear":"","relationship":"same-target"},{"drugId":"benzonatate","brandName":"benzonatate","genericName":"benzonatate","approvalYear":"1958","relationship":"same-target"},{"drugId":"bepridil","brandName":"bepridil","genericName":"bepridil","approvalYear":"1990","relationship":"same-target"},{"drugId":"bupivacaine","brandName":"bupivacaine","genericName":"bupivacaine","approvalYear":"1972","relationship":"same-target"},{"drugId":"carbamazepine","brandName":"carbamazepine","genericName":"carbamazepine","approvalYear":"1968","relationship":"same-target"},{"drugId":"cinchocaine","brandName":"cinchocaine","genericName":"cinchocaine","approvalYear":"","relationship":"same-target"},{"drugId":"dextropropoxyphene","brandName":"dextropropoxyphene","genericName":"dextropropoxyphene","approvalYear":"1957","relationship":"same-target"},{"drugId":"disopyramide","brandName":"disopyramide","genericName":"disopyramide","approvalYear":"1977","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT02202993","phase":"PHASE1","title":"TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM","status":"COMPLETED","sponsor":"Cavion, Inc.","startDate":"2014-08","conditions":["Glioblastoma Multiforme (GBM)"],"enrollment":18,"completionDate":"2017-09-29"},{"nctId":"NCT01480050","phase":"PHASE1","title":"Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-05-31","conditions":["Brain and Central Nervous System Tumors"],"enrollment":28,"completionDate":"2017-06-01"},{"nctId":"NCT01550458","phase":"PHASE1","title":"Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers","status":"COMPLETED","sponsor":"Cavion, Inc.","startDate":"2012-02","conditions":["Healthy"],"enrollment":30,"completionDate":"2012-06-24"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000022079","MMSL":"10198","NDDF":"006710","UNII":"27B90X776A","VUID":"4024074","CHEBI":"CHEBI:6920","VANDF":"4021047","INN_ID":"7134","RXNORM":"54980","UMLSCUI":"C0286185","chemblId":"CHEMBL1534525","ChEMBL_ID":"CHEMBL45816","KEGG_DRUG":"D05024","DRUGBANK_ID":"DB01388","PDB_CHEM_ID":"MWV","PUBCHEM_CID":"60663","SNOMEDCT_US":"319318006","IUPHAR_LIGAND_ID":"2522","SECONDARY_CAS_RN":"116666-63-8","MESH_DESCRIPTOR_UI":"D020748"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"13.0 hours","clearance":"4.0 mL/min/kg","bioavailability":"75%","fractionUnbound":"0.005%","volumeOfDistribution":"3.1 L/kg"},"publicationCount":825,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CX01","allCodes":["C08CX01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 12","pmid":"41819735","title":"Drug-drug interaction by metabolites: Challenges and solutions during therapeutics innovation.","journal":"Drug metabolism and disposition: the biological fate of chemicals"},{"date":"2026 Jan 6","pmid":"41403024","title":"Recurrent CACNA1HE282K is a gain-of-function mutation associated with primary hyperaldosteronism.","journal":"European journal of endocrinology"},{"date":"2025 Dec","pmid":"40907630","title":"The role and behavior of voltage-gated calcium channels in ischemia/reperfusion.","journal":"Cellular signalling"},{"date":"2025","pmid":"40859969","title":"Identification and Validation of Antidepressant Small Molecules Using Bioinformatics and Mouse Depression Models.","journal":"Drug design, development and therapy"},{"date":"2025 Aug","pmid":"40624735","title":"A New Method for Antispastic Effect in Coronary Artery Bypass Grafts by Using a L- and T-Type Calcium Channel Blocker Efonidipine.","journal":"Basic & clinical pharmacology & toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1997","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-08-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:58:33.618991+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}